CUMBERLAND PHARMACEUTICALS INC stock forecast: down to 2.69 USD CPIX stock price prognosis
Forecast for Tue 09 Nov 2021 price
CUMBERLAND PHARMACEUTICALS INC stock price forecast for further price development down to -0.37% (time horizon: 1 day) and price target of 2.69 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) CUMBERLAND PHARMACEUTICALS INC share price prediction for 2021-11-09 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
Our primary target markets are hospital acute care, gastroenterology and rheumatology. In January 2020, we initiated a full-scale launch of this ready-to-use product. The product was developed and registered by Astellas. It is the first DMD clinical study approved for FDA Orphan Product Development funding. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and and patient enrollment completed. We currently market seven FDA approved products for sale in the United States. Build an international contribution to our business. Manage our operations with financial discipline. During 2019 we entered into a new packaging arrangement for this product. The 445 Acetadote Patent is scheduled to expire in August 2025. NAC is accepted worldwide as the standard of care for acetaminophen overdose. These drugs are manufactured by numerous pharmaceutical companies. The major generic competitors are vancomycin, linezolid, and daptomycin. If the NDA is found to be incomplete, it will not be accepted. The following highlights certain provisions of the legislation that may affect us. These laws include anti-kickback statutes and false claims statutes. Risk Factor SummaryInvesting in our common stock involves a high degree of risk. We have a relatively small internal infrastructure. The pharmaceutical industry is intensely competitive. Expansion of the market for our products may be subject to certain limitations. Adoption of such legislation could further limit reimbursement for pharmaceuticals. There is uncertainty with respect to the timing and impact of any changes. We could be adversely affected if we or our products are subject to negative publicity. Virtually all aspects of our business activities are regulated by government agencies. These regulations became effective on April 1, 2016. Also, others could acquire or independently develop similar technology. We might not be able to obtain such a license on terms acceptable to us or at all. As a result, we may incur losses in future periods.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 47.36/100
Good financial position.
Historical view, profit is not growing.
Company revenue is not growing faster compared with the
Stock price is under book price value.
Institutional ownership list is based on filling form information
Insider trading for CUMBERLAND PHARMACEUTICALS INC
Cearnal Martin E
CUMBERLAND PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for CUMBERLAND PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for CUMBERLAND PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for CUMBERLAND PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for CUMBERLAND PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for CUMBERLAND PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for CUMBERLAND PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for CUMBERLAND PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio